late
novel
type
coronaviru
emerg
wuhan
china
caus
patient
show
pneumonialik
symptom
later
viru
spread
around
world
world
health
organ
announc
pandem
march
march
case
approxim
death
viru
identifi
larg
number
infect
patient
three
month
sinc
first
report
case
demonstr
diseas
extrem
contagi
caus
sever
acut
respiratori
syndrom
coronaviru
belong
famili
coronavirida
famili
respons
two
viral
outbreak
recent
year
first
caus
sever
acut
respiratori
syndrom
coronaviru
sarscov
second
outbreak
occur
due
spread
middl
east
respiratori
syndrom
coronaviru
merscov
anoth
viru
famili
two
epidem
infect
mani
peopl
time
peak
diseas
regress
limit
report
laboratori
accid
animaltohuman
transmiss
publish
today
treatment
report
although
casereport
observ
studi
report
antivir
drug
effect
improv
outcom
patient
definit
cure
discov
far
recent
chines
research
team
propos
treatment
protocol
manag
patient
includ
moxifloxacin
levofloxacin
consid
toler
arbidol
administr
howev
underli
evid
mention
treatment
protocol
unclear
clinic
trial
perform
matter
sever
antivir
therapi
consid
potenti
effect
treat
includ
oseltamivir
ganciclovir
arbidol
lopinavir
ritonavir
mani
clinic
trial
current
underway
evalu
efficaci
differ
medic
outcom
patient
result
publish
yet
hand
qualiti
studi
rather
unclear
treatment
use
sarscov
merscov
may
use
treatment
due
fact
virus
famili
caus
respiratori
diseas
nevertheless
consensu
yet
reach
matter
primari
object
current
systemat
review
evalu
evid
underli
efficaci
safeti
antivir
therapi
treatment
current
pandem
anoth
goal
present
studi
investig
clinic
trial
perform
recent
year
effect
antivir
therapi
sarscov
merscov
propos
potenti
exist
treatment
studi
design
present
systemat
review
perform
two
section
first
section
current
clinic
evid
efficaci
antivir
treatment
manag
name
antivir
therapi
section
present
second
part
provid
review
clinic
trial
conduct
sarscov
merscov
find
propos
antivir
therapi
name
sarsmer
antivir
therapi
section
select
criteria
antivir
therapi
section
type
perform
clinic
studi
aim
evalu
efficaci
safeti
antivir
drug
includ
exclus
criteria
compris
vitro
studi
anim
studi
guidelin
review
studi
sarsmer
antivir
therapi
section
inclus
criteria
consist
clinic
trial
efficaci
safeti
antivir
drug
administ
manag
arscov
merscov
exclus
criteria
section
contain
observ
studi
guid
anim
studi
review
articl
sinc
sar
mer
outbreak
happen
recent
year
opportun
conduct
clinic
trial
clinic
trial
includ
section
provid
highest
level
evid
section
antivir
therapi
suggest
provid
underli
evid
highest
valid
search
strategi
extens
search
perform
medlin
via
pubm
embas
scopu
central
web
scienc
databas
keyword
select
use
expert
opinion
mesh
emtre
relat
articl
titl
keyword
antivir
therapi
section
keyword
associ
sinc
small
number
articl
publish
treatment
use
antivir
treatment
preval
mention
abstract
articl
keyword
relat
antivir
therapi
includ
search
also
search
date
chosen
earli
march
sinc
first
report
publish
late
keyword
sarsmer
antivir
therapi
section
includ
keyword
relat
sarscov
merscov
combin
standard
filter
clinic
trial
similar
previou
section
keyword
relat
antivir
therapi
includ
search
due
limit
number
studi
time
rang
search
set
incept
databas
march
search
strategi
medlin
present
tabl
addit
systemat
search
extens
search
also
perform
googl
googl
scholar
search
engin
articl
bibliographi
data
collect
two
independ
research
review
titl
abstract
record
obtain
databas
select
relat
articl
next
full
text
articl
collect
review
care
final
relat
articl
suitabl
base
inclus
exclus
criteria
includ
present
systemat
review
two
research
summar
articl
collect
data
includ
name
first
author
public
year
countri
studi
conduct
type
studi
sampl
size
age
sex
distribut
patient
drug
use
dose
durat
administr
rout
administr
treatment
outcom
disagr
resolv
discuss
third
research
studi
characterist
initi
search
yield
articl
elimin
duplic
record
review
studi
includ
current
systemat
review
figur
articl
conduct
china
one
articl
conduct
south
korea
one
studi
perform
singapor
one
clinic
trial
found
evalu
efficaci
lopinavirritonavir
treat
patient
sever
among
includ
articl
caseseri
casereport
articl
studi
patient
treat
antivir
agent
commonli
use
antivir
lopinavir
ritonavir
oseltamivir
ribavirin
arbidol
respect
rout
durat
administr
report
studi
common
rout
administr
among
studi
oral
administr
durat
administr
vari
two
day
studi
use
therapi
antibiot
immunoglobin
interferon
glucocorticoid
methylprednisolon
antiparasit
antifung
drug
addit
antivir
therapi
manag
patient
tabl
antivir
therapi
manag
clinic
trial
found
perform
patient
sever
use
lopinavirritonavir
regimen
random
openlabel
clinic
trial
patient
divid
two
group
lopinavirritonavir
patient
group
standard
treatment
group
addit
lopinavirritonavir
mg
mg
twice
daili
day
standard
treatment
antibiot
invas
noninvas
ventil
extracorpor
membran
oxygen
ecmo
vasopressor
also
use
find
studi
show
patient
receiv
lopinavirritonavir
similar
recoveri
process
receiv
standard
treatment
mortal
viral
rna
load
significantli
differ
two
group
research
conclud
lopinavirritonavir
administr
patient
sever
effect
standard
treatment
previous
mention
studi
casereport
caseseri
moreov
studi
provid
analysi
regard
efficaci
antivir
therapi
treatment
cours
patient
instanc
chen
et
al
report
death
among
nine
patient
treat
lopinavirritonavir
howev
sampl
size
mention
articl
quit
small
accord
exist
statist
mortal
rate
among
patient
age
year
vari
henc
everi
patient
age
group
one
patient
die
therefor
sampl
size
probabl
larg
enough
observ
least
one
death
anoth
studi
hu
et
al
studi
asymptomat
patient
report
mortal
icu
admiss
seriou
complic
patient
treat
antivir
agent
nonetheless
addit
small
sampl
size
sinc
patient
asymptomat
sever
rather
mild
therefor
recoveri
patient
might
due
mild
diseas
rather
efficaci
antivir
drug
use
guan
et
al
studi
patient
treat
oseltamivir
show
icu
admiss
need
mechan
ventil
death
rate
among
oseltamivirtr
group
whilst
rate
group
treat
oseltamivir
word
oseltamivir
administr
ineffect
decreas
icu
admiss
rate
need
ventil
death
rate
among
patient
shang
et
al
perform
studi
patient
indic
antivir
drug
effect
mortal
rate
patient
studi
mortal
rate
among
group
treat
antivir
drug
wherea
group
receiv
antivir
treatment
mortal
rate
furthermor
singapor
young
et
al
studi
patient
administ
lopinavirritonavir
five
patient
two
recov
two
deterior
one
patient
toler
antivir
regimen
complet
treatment
cours
start
antivir
treatment
liver
test
result
becam
abnorm
three
patient
also
li
et
al
examin
five
children
two
patient
treat
antivir
drug
three
patient
receiv
antivir
therapi
indic
antivir
agent
chang
outcom
durat
hospit
stay
lim
et
al
present
nonsmok
woman
medic
histori
viral
load
start
declin
symptom
start
allevi
gradual
start
lopinavirritonavir
treatment
eventu
patient
discharg
research
report
clear
reduc
burden
due
heal
process
administr
antivir
therapi
furthermor
han
et
al
zhang
et
al
report
complet
recoveri
one
patient
diabet
treat
oseltamivirganciclovir
two
patient
treat
oseltamivir
arbidol
respect
also
studi
avail
despit
accept
sampl
size
report
final
outcom
larg
portion
patient
instanc
wu
et
al
report
death
among
patient
treat
ribavirin
patient
still
discharg
outcom
still
unclear
time
submiss
articl
xu
et
al
yang
et
al
wang
et
al
also
observ
death
studi
howev
major
patient
review
still
treatment
unclear
final
outcom
time
public
articl
studi
sarscov
merscov
extens
search
conduct
databas
order
find
exist
evid
regard
antivir
therapi
treatment
diseas
caus
sarscov
merscov
famili
section
clinic
trial
suppos
found
nondupl
articl
review
clinic
trial
perform
antivir
treatment
manag
sarscov
merscov
patient
figur
one
clinic
trial
protocol
commiss
research
team
saudi
arabia
exist
studi
name
miracl
trial
design
evalu
efficaci
lopinavir
ritonavir
combin
therapi
treatment
merscov
patient
studi
current
ongo
result
publish
yet
therefor
clinic
trial
exist
basi
antivir
drug
suggest
even
sarscov
merscov
find
present
studi
indic
one
clinic
trial
complet
efficaci
safeti
antivir
agent
manag
patient
show
ineffect
lopinavirritonavir
improv
patient
outcom
moreov
clinic
trial
exist
treatment
sarscov
merscov
furthermor
caseseri
casereport
provid
report
antivir
treatment
manag
patient
none
taken
account
assess
clinic
use
antivir
treatment
gener
studi
examin
efficaci
antivir
therapi
alon
treatment
exist
articl
use
treatment
antibiot
immunoglobulin
interferon
glucocorticoid
antifung
antiparasit
drug
studi
henc
report
present
attribut
sole
antivir
drug
therefor
exist
literatur
regard
efficaci
antivir
therapi
manag
patient
seriou
limit
includ
one
clinic
trial
conduct
matter
depict
lopinavirritonavir
superior
standard
treatment
manag
patient
exist
caseseri
casereport
antivir
agent
use
combin
medic
therefor
observ
outcom
sole
attribut
antivir
therapi
sinc
placebo
group
caseseri
casereport
one
determin
outcom
due
antivir
therapi
natur
heal
process
followup
incomplet
studi
great
proport
patient
unclear
outcom
sampl
size
small
studi
even
case
report
recent
zhang
et
al
post
guidelin
lancet
respiratori
medicin
journal
recommend
administr
arbidol
manag
patient
howev
guidelin
limit
gener
underli
evid
guidelin
unclear
secondli
base
present
systemat
review
arbidol
use
second
line
therapi
includ
studi
henc
drug
appear
inappropri
first
line
therapi
nevertheless
lopinavirritonavir
ineffect
manag
patient
highlight
need
search
antivir
therapi
mani
exist
guidelin
instruct
propos
antivir
drug
manag
patient
base
studi
perform
sarscov
merscov
therefor
current
studi
aim
summar
evid
obtain
clinic
trial
determin
level
evid
underli
mention
propos
surprisingli
complet
clinic
trial
sarscov
merscov
found
propos
base
simul
studi
vitro
studi
preclin
studi
best
observ
studi
caseseri
epidem
subsid
research
reluct
perform
investig
matter
major
pitfal
research
sever
reason
first
import
reason
declin
number
patient
sever
limit
possibl
perform
clinic
trial
secondli
previou
two
epidem
name
sarscov
merscov
never
becam
pandem
major
case
limit
geograph
region
therefor
suppress
epidem
declin
number
patient
two
diseas
elimin
list
prioriti
intern
organ
intern
organ
world
health
organ
insist
import
subject
provid
grant
independ
research
mayb
effect
antivir
agent
sarscov
merscov
would
exist
could
help
manag
decreas
burden
societi
lesson
learn
pandem
neglig
health
polici
maker
set
clinic
trial
sarscov
merscov
epidem
current
pandem
futur
epidem
research
welldesign
clinic
trial
plannedout
diseas
peak
find
use
necessari
find
current
systemat
review
indic
clear
whether
current
use
antivir
agent
benefici
improv
outcom
patient
one
clinic
trial
caseseri
suggest
drug
may
impact
final
outcom
patient
furthermor
lack
publish
clinic
trial
sarscov
merscov
epidem
recent
year
imped
suggest
potenti
antivir
treatment
current
situat
seriou
red
flag
intern
organ
world
health
organ
time
current
pandem
futur
epidem
organ
pursu
proactiv
action
plan
welldesign
clinic
trial
abl
use
result
manag
futur
pandem
